Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Biller

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Molecular Cancer Therapeutics|October 21, 2020
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate DehydrogenaseGabrielle McDonald, Victor Chubukov, John Coco, et al.
Journal of Medicinal Chemistry|November 2, 2007
Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180)Jun Li, Stephanie Y Chen, James J Li, et al.
Science (New York, N.Y.)|October 23, 1998
An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbitsJ R Wetterau, R E Gregg, T W Harrity, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Molecular Cancer Therapeutics|October 21, 2020
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate DehydrogenaseGabrielle McDonald, Victor Chubukov, John Coco, et al.
Journal of Medicinal Chemistry|November 2, 2007
Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180)Jun Li, Stephanie Y Chen, James J Li, et al.
Science (New York, N.Y.)|October 23, 1998
An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbitsJ R Wetterau, R E Gregg, T W Harrity, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
Pageof 8